Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: results from a multicenter study in Italy.

Valentina Silvestri, Piera Rizzolo, Marco Scarnò, Giovanni Chillemi, Anna Sara Navazio, Virginia Valentini, Veronica Zelli, Ines Zanna, Calogero Saieva, Giovanna Masala, Simonetta Bianchi, Siranoush Manoukian, Monica Barile, Valeria Pensotti, Paolo Peterlongo, Liliana Varesco, Stefania Tommasi, Antonio Russo, Giuseppe Giannini, Laura Cortesi, Alessandra Viel, Marco Montagna, Paolo Radice, Domenico Palli, Laura Ottini

Journal: European journal of cancer (Oxford, England : 1990) 2016;51(16):2289-95

PMID: 26248686

Abstract

Increasing evidence indicates that common genetic variants may contribute to the heritable risk of breast cancer (BC). In this study, we investigated whether single nucleotide polymorphisms (SNPs), within the 8q24.21 multi-cancer susceptibility region and within BC-associated loci widespread in the genome, may influence the risk of BC in men, and whether they may be associated with specific clinical-pathologic characteristics of male BC (MBC). In the frame of the ongoing Italian Multicenter Study on MBC, we performed a case-control study on 386 MBC cases, including 50 BRCA1/2 mutation carriers, and 1105 healthy male controls, including 197 unaffected BRCA1/2 mutation carriers. All 1491 subjects were genotyped by Sequenom iPLEX technology for a total of 29 susceptibility SNPs. By logistic regression models, we found a significant association with MBC risk for five SNPs: rs1562430 (p=0.002) and rs445114 (p=0.026) both within the 8q24.21 region; rs1011970/9p21.3 (p=0.011), rs614367/11q13.3 (p=0.016) and rs1314913/14q24.1 (p<0.0001). Differences in the distribution of rs614367/11q13.3 genotypes according to oestrogen receptor (ER) status (p=0.006), and of rs1011970/9p21.3 genotypes according to human epidermal growth factor receptor 2 (HER2) status (p=0.002) emerged. Association of rs1011970/9p21.3 risk genotype with HER2+MBC was confirmed by a multivariate analysis. rs1314913/14q24.1 was associated with increased MBC risk in analyses restricted to male BRCA1/2 mutation carriers (p=0.041). In conclusion, we provided the first evidence that the 8q24.21 region is associated with MBC risk. Furthermore, we showed that the SNPs rs1562430/8q24.21 and rs1314913/14q24.1 strongly influence BC risk in men and suggested that the SNP rs1314913/14q24.1 may act as a risk modifier locus in male BRCA1/2 mutation carriers.

Copyright © 2015 Elsevier Ltd. All rights reserved.

Address: Department of Molecular Medicine, Sapienza University of Rome, Italy.; CINECA (Inter University Consortium for Super Computing), Rome, Italy.; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.; Division of Pathological Anatomy, Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy.; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy.; Fondazione Istituto FIRC di Oncologia Molecolare (IFOM) and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.; Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy.; Unit of Hereditary Cancers, IRCCS AOU San Martino - IST, Genoa, Italy.; Molecular Genetics Laboratory, Istituto Tumori "Giovanni Paolo II", Bari, Italy.; Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Italy.; Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy.; Unit of Experimental Oncology 1, CRO Aviano, National Cancer Institute, Aviano (PN), Italy.; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy.; Department of Molecular Medicine, Sapienza University of Rome, Italy. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.